Company news
Arrivent Biopharma, Inc. (NASDAQ:AVBP) news
Every Arrivent Biopharma, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
ArriVent BioPharma Reports Second Quarter 2026 Financial Results
August 12, 2026
ArriVent BioPharma Reports First Quarter 2026 Financial Results
May 11, 2026
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial C...
May 7, 2026
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC...
March 17, 2026
ArriVent BioPharma Reports Full Year 2025 Financial Results
March 5, 2026
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR ...
December 22, 2025
ArriVent BioPharma Reports Third Quarter 2025 Financial Results
November 10, 2025
ArriVent Appoints Brent S. Rice as Chief Commercial Officer
September 22, 2025
Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung...
September 9, 2025
ArriVent BioPharma Reports Second Quarter 2025 Financial Results
August 11, 2025
ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be ...
July 21, 2025
ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants
July 1, 2025
ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
July 1, 2025
ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Can...
June 23, 2025
ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC
June 20, 2025
ArriVent BioPharma Reports First Quarter 2025 Financial Results
May 12, 2025
ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors
April 28, 2025
ArriVent BioPharma Reports Full Year 2024 Financial Results
March 3, 2025
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointesti...
January 21, 2025
ArriVent BioPharma Reports Third Quarter 2024 Financial Results
November 14, 2024
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant No...
September 9, 2024
ArriVent BioPharma Reports Second Quarter 2024 Financial Results
August 14, 2024
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Con...
August 12, 2024
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab
June 5, 2024
ArriVent Appoints John Hohneker, M.D., to its Board of Directors
May 16, 2024
ArriVent BioPharma Reports First Quarter 2024 Financial Results
May 8, 2024
ArriVent Appoints Kristine Peterson to its Board of Directors
April 22, 2024
ArriVent BioPharma Reports Full Year 2023 Financial Results
March 28, 2024